Introduction
Diabetic retinopathy is a common cause of severe vision loss and the leading cause of blindness in individuals between 20 and 65 years of age in developed countries, and diabetic macular edema (DME) is the most common cause of visual loss in diabetic retinopathy, affecting approximately 6.8% of people with diabetes (1-3). Diabetic macular edema results from breakdown of the blood-retinal barrier, leading to vascular leakage, fluid accumulation, and thickening of the macula.
In the past, focal/grid laser photocoagulation was the landmark treatment for clinically significant DME (4) . However, no significant visual gains were observed with laser photocoagulation, prompting ongoing searches for better and more effective therapies. Although the pathophysiology of DME is several randomized, controlled, clinical trials, both in refractory and naive eyes, alone and in combination with laser photocoagulation (20) (21) (22) , no conclusion can be drawn so far on their early effects on CRT and VA, namely in the first 3 months after treatment.
Assessing the short-term efficacy of DEX implant and understanding the time course of its effect may enable the choice of the best timing for treating patients with severe central-involved DME and in the case of longstanding DME and/or recalcitrant DME in which combination with other treatments such as laser photocoagulation and/or antiangiogenic drugs may be crucial.
The purpose of this study was to evaluate the early therapeutic effects of DEX intravitreal implants on macular morphology and visual function in patients with DME.
Methods

Patients and study design
This was a prospective, single-arm, interventional clinical series. The study protocol was approved by the local ethical committee and informed consent was obtained from all patients. Patients with moderate or severe nonproliferative diabetic retinopathy and moderate or severe central-involved DME, as assessed by fluorescein angiography and spectraldomain optical coherence tomography (SD-OCT), were recruited in the study. All the patients underwent detailed study by means of SD-OCT in order to define the morphology of DME. Both naive patients and patients with recalcitrant/ persistent DME were enrolled. Recalcitrant or persistent DME was defined as lack of response after ≥1 treatment of macular laser photocoagulation and/or intravitreal anti-VEGF injections (at least 3 consecutive injections). The term chronic DME was reserved for those patients with recalcitrant DME of ≥2 years duration. Patients with DME for no longer than 6 months before the study entry and with no previous treatment were included as naive DME. Other inclusion criteria were best-corrected visual acuity (BCVA) of 20/32 to 20/200 Snellen equivalent and CRT of ≥300 μm detected by SD-OCT. Exclusion criteria included history of glaucoma or IOP >25 mm Hg, intravitreal treatment with anti-VEGF agents or photocoagulation within 3 months prior to patient inclusion, ocular infection or inflammation ≤30 days before enrollment, uncontrolled diabetes (blood glucose ≥250 mg/dL, HbA1c ≥75 mmol/mol), presence of vitreomacular traction or epiretinal membrane, and other ocular diseases that may affect treatment results, such as retinal detachment or vitreous hemorrhage. If both eyes of the patient met the eligibility criteria, the eye with the worse VA at baseline was designated as the study eye.
Ozurdex® (Allergan, Inc.) consists of micronized dexamethasone in a biodegradable copolymer of polylactic-coglycolic acid that releases DEX slowly for up to 6 months. Single implants (0.7 mg) were implanted in the study eyes.
The main outcome measure was the change in CRT on SD-OCT in response to Ozurdex® injection. Secondary endpoints included BCVA and changes in IOP following intravitreal implant. Key safety variables were assessed at each study visit and included ocular and systemic adverse events. Patient monitoring included BCVA assessment by Early Treatment Diabetic Retinopathy Study letters and a complete ophthalmologic examination, including intraocular pressure (IOP) measurement. Central retinal thickness was evaluated by SD-OCT scan. Assessments were performed at 1-3 hours (day 0) and 3, 7, and 30 days after implant injection. Optical coherence tomography scans were obtained with SD-OCT equipment (Cirrus high-definition OCT; Carl Zeiss). Central retinal thickness was computed manually with 5-line, high-quality raster scans using the caliper function on the Zeiss 5.0 software and compared with the CRT value detected automatically with the Cirrus analysis software version 5.0 (Carl Zeiss Meditec AG). All scans were reviewed before considering the use of the manual measurement of macular thickness.
Statistical analysis
The sample size was computed to detect a 100-μm difference in CRT (SD 150 μm) (23) . With α = 0.05 (2-sided) and a power of 0.95, the calculated sample size was at least 17 eyes. Central retinal thickness and VA of the sample of 18 participants underwent a repeated-measures analysis of variance (ANOVA) with testing session (before, 3 days after, 7 days after, and 30 days after treatment) as a predictor. For CRT and IOP, a testing session 1 to 3 hours after treatment was also taken into consideration. Simple (for VA) or repeated contrasts (for CRT), as well as polynomial fitting functions, were then used for testing the time course of the improvement following the treatment. Calculation of BCVA was performed using Snellen VA, converting to logMAR format for statistical calculation.
Results
Overall, 18 patients were enrolled. The mean age of treated patients was 65 years; 78% were men. Mean duration of diabetes mellitus (DM) was 14.4 years and DM was under systemic control, as assessed by fasting blood sugar/postprandial blood sugar and HbA1c levels. Eighteen eyes were treated. Patients' demographic and clinical baseline characteristics are reported in Table I .
Changes in macular morphology
A repeated-measures ANOVA with testing session as a predictor revealed that CRT was significantly reduced after the treatment (F 4,68 31.8086, p<0.001, η 2 p 0.65). Repeated contrasts showed that CRT was reduced 1 to 3 hours after the treatment (day 0 from injection in Fig. 1 
Changes in BCVA
Before intraocular Ozurdex® implantation, mean BCVA was 20/60 (0.57 ± 0.25 logMAR). Similarly to what was found for CRT, a second repeated-measures ANOVA with testing session as a predictor revealed that VA significantly improved after the treatment (F 3,51 3.37, p<0.05, η 0.213), up to 0.14 logMAR on average (Fig. 2) , with mean BCVA corresponding to 20/50 or better (0.44 ± 0.23 and 0.42 ± 0.25 logMAR, respectively) (Tab. II). The improvement of VA as a function of time-distance from the treatment (Fig. 2) can be described by an exponential function (y = 0.4176137 + 0.1247014*e^[-0.2084781*x]; R² = 0.99), suggesting that, similarly to what occurs for CRT, the largest improvement in VA takes place right after the treatment (in fact here 7 days after). This suggests that VA improves as a consequence of CRT reduction, but at a slower rate with respect to CRT.
Complications
A repeated-measures ANOVA with testing session as a predictor revealed that IOP was significantly altered by the treatment (F 4,68 3.65, p<0.01, η 2 p 0.18). Simple contrasts show that IOP was reduced 1 to 3 hours after the treatment (day 0 from injection in Fig. 3 
Discussion
There is increasing evidence that demonstrates the longterm efficacy of intravitreal steroids in the treatment of DME (19, 21, (24) (25) (26) (27) . In contrast, no clinical data exist about the very early effects of the intravitreal implant of DEX. To our knowledge, this is the first study showing that treatment with the DEX implant in patients with naive or chronic/recalcitrant DME results in early CRT decrease and VA improvement, with further progress during our 30-day short-term follow-up. (28) evaluated the early effects of DEX implants, but in patients with macular edema due to retinal vein occlusion. In these patients, DEX implant showed a fast and persistent effect in reducing CRT and improving BCVA, starting 1 day after treatment (65% of the maximal reduction of CRT), up to the end of the 90-day follow-up. In our patients, CRT reduction was measurable as early as within 3 hours after DEX implant application (first measurement), was greatest at day 3, and then progressed at a slower rate up to day 30. It is remarkable that more than 30% of the maximal reduction in CRT that could be obtained during the first month after implant was already achieved within 3 hours after injection and more than 60% within 3 days.
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Best-corrected visual acuity, the secondary endpoint, also improved progressively, but a significant change was noticeable 7 days after treatment. The correlation between CRT reduction and VA improvement suggests that VA improves as a consequence of CRT reduction, but at a slower rate.
The mechanism by which steroids reduce macular edema in DME is not fully recognized at this time. It is known that steroids modulate both genomic and nongenomic pathways. At a nongenomic level, it has been proposed that steroids may inhibit the osmotic swelling of retinal glial cells (29) , and this may occur rather rapidly. Our data on retinal morphology have been obtained quite early compared to most of the previously published data, showing that anatomical changes occur very soon after DEX treatment, and this seems to support such a proposed mechanism of action. In our study, the very short-term effect was obtained also in naive patients, suggesting that the possible effect of DEX is not limited to chronic and/or recalcitrant DME.
Concerning long-term effects, the MEAD study reported clinically relevant long-term improvements in both macular edema and vision by DEX implants (20, 21) . In the PLACID study (22) , VA improved significantly more in the DEX + laser group than in the laser alone group, while CRT showed similar reductions in both groups, suggesting that photocoagulation might only act on the edema, while DEX is required to improve VA. In our patients, both CRT and VA improved promptly after DEX implant application alone in patients with DME resistant to laser photocoagulation and/or VEGF treatment.
Management of DME is mainly aimed at obtaining a dry macula, improving VA, and maintaining dryness and stable vision. Choosing the optimal treatment for the patient is crucial. The treatment arsenal for DME is enormous, with Best-corrected visual acuity significantly improved after 7 and 30 days posttreatment. c Intraocular pressure was significantly reduced 1-3 hours and 3 days after the treatment with respect to baseline but returned to values nonsignificantly different with respect to baseline 7 days and 30 days after the treatment. Early effects of DEX implant in DME 78 various types of medications. Management should be carried out on the basis of identifying the pathologic factor involved as the main driver and treating it. Chronic/recalcitrant and naive DME have different therapeutic approaches linked to different pathogenetic pathways in which several vascular, hypoxic, and inflammatory mediators may cause tissue damage. The effects measured in our study were much earlier than those observed with anti-VEGF therapy. Such a rapid effect may raise some interest about the efficacy of intravitreal steroids both in nonchronic and chronic disease, suggesting that there may be a very early efficacy window, when other combined treatments could be effectively added/combined, such as anti-VEGF agents or laser photocoagulation.
Concerning treatment safety, IOP, though statistically changed over the study course, finished by returning to values nonsignificantly different with respect to baseline. The reduction observed immediately after intravitreal injection could be hypothesized as related to the size of the needle (22-G).
Major limitations of our clinical series are the small number of eyes studied and the lack of a control arm. However, these preliminary results, obtained in a real-world setting, shed some light on the short-term effects of DEX implants and may encourage further clinical research.
To our knowledge, this is the first study reporting very early effects of a DEX implant on CRT despite recalcitrant DME. It should be worth exploring such early effects in patients with DME nonresistant to first-line therapy, where results could be even better. In this series, we also obtained rapid and progressive improvements in VA, with virtually no effects on IOP. Knowing the time course of the action of DEX implants may allow the selection of appropriate timing for combined treatment with laser photocoagulation, which may be particularly useful in patients with treatment-resistant DME. Further data regarding retinal morphology during the early days after therapy with Ozurdex® would be of great help in better elucidating the pharmacodynamic process by which dexamethasone reduces macular edema and improves retinal morphology in humans. Intravitreal steroid implants, either in monotherapy or in combination with anti-VEGF agents and selective laser photocoagulation, may be a useful adjunct in the treatment armamentarium for both early and chronic DME.
